Tiago Girao has sold IMVT and made no open-market buys since Jun 2026

Tiago Girao is a corporate finance executive and Chief Financial Officer of Immunovant, Inc. (NASDAQ: IMVT), a clinical-stage biotechnology company focused on autoimmune diseases.( He was appointed CFO and principal financial and accounting officer of Immunovant in April 2025, bringing more than 20 years of experience leading finance, accounting, and operations for U.S. and global public and private companies.( As a corporate insider, his role includes oversight of Immunovant’s financial strategy, reporting, and capital markets activities, and he has been the subject of recent insider trading disclosures related to option exercises, equity grants, and share sales in Immunovant stock.(

Before joining Immunovant, Girao served as Chief Financial Officer for multiple Roivant Sciences subsidiaries, including Telavant, Proteovant Therapeutics, and Respivant Sciences, and previously held the CFO role at Cytori Therapeutics, Inc. from 2014 to 2019.( His earlier career includes senior finance positions at NuVasive, Inc. and more than a decade in the audit practices of Ernst & Young and KPMG, where he built his foundational expertise in accounting and financial reporting.( Girao has also served as a board member of Landos Biopharma, Inc. from 2021 until its acquisition by AbbVie Inc. in 2024.( He holds an accounting degree from Universidade de Fortaleza in Brazil and is a licensed Certified Public Accountant in California, credentials that underpin his leadership in life sciences finance and corporate governance.(

Written by Perplexity from public sources.